H.C. Wainwright Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)

April 20, 2026 6:39 AM

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $4.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found